CVMP advice on injection-site fibrosarcomas in cats.
In response to increasing concern, the Committee for Veterinary Medicinal Products (CVMP) has produced this advisory notice for veterinary surgeons on the development in cats of fibrosarcomas at sites of administration of veterinary medicinal products. The advice relates principally, but not exclusively, to the subcutaneous injection of vaccines. The issue is of relevance only to cats and no extrapolation should be made to other species or to man. At the current state of knowledge, it is not possible to provide specific advice on the risk that any product, or any type of product, might represent in terms of inducing a fibrosarcoma at the site of administration. However, following the precautionary principle, the CVMP considers that information on this issue should be made available to veterinary surgeons in order that they can have an informed discussion with owners of the benefits and risks of therapeutic interventions in cats, particularly in relation to vaccination and re-vaccination. The CVMP wishes to emphasise that modern vaccines continue to represent the only safe and effective means of protecting cats against serious infectious diseases and this should be taken fully into account in any discussion between veterinary surgeons and owners of cats.
D000818:Animals; D002371:Cat Diseases / Q000209:etiology*; D002415:Cats; D005354:Fibrosarcoma / Q000209:etiology* / Q000662:veterinary*; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects / Q000662:veterinary; D007258:Informed Consent; D007279:Injections, Subcutaneous / Q000009:adverse effects* / Q000662:veterinary*; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000209:etiology* / Q000662:veterinary*; D014611:Vaccination / Q000009:adverse effects / Q000662:veterinary; D014612:Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D014730:Veterinary Medicine / Q000592:standards*
D014612:Vaccines